The Indian bio-pharmaceutical industry must allocate resources towards innovative research and development to remain competitive and leverage emerging global market opportunities. Emphasizing the strengthening of intellectual property (IP) assets, Dr. Jitendra Kumar, Managing Director of DBT-BIRAC, stated that prioritizing advanced research and innovation is crucial for India to establish itself as a dominant force in the bio-pharma sector. By cultivating a supportive R&D environment, strengthening IP protection, collaborating internationally, and integrating novel technologies, India can advance from leading generic drug production to pioneering biopharmaceutical innovations. This transition will not only boost the industry’s market position but also enhance global healthcare quality, Dr. Kumar explained.
Dr. Kumar highlighted the BioE3 policy’s alignment with the existing production-linked incentive (PLI) scheme, noting that while PLI may not fully support bio-manufacturing, BioE3 promotes high-performance bio-production by offering subsidies and funding. This policy establishes a foundation for sustainable advancement that aligns technological progress with environmental responsibility and economic growth, helping India compete on the global stage. For India to attain a leadership status in the biotech field, lowering production costs through such schemes is essential.
Despite its substantial standing in generic drug manufacturing—ranking third by volume and 14th by value—India must enhance the value of its medicinal products. Expanding IP wealth through groundbreaking research is vital, as Dr. Kumar noted during a recent BTS session.
Fundamental research should also be a priority for Indian biotechnology. Although academic centers and public institutes exist, India lacks institutional mechanisms akin to US universities, which partner with business schools to spawn startups. Strengthening this model is necessary for India to advance.
Dr. Kumar pointed out the need for more Indian states to develop biotechnology ecosystems like Karnataka’s, which fosters academic and industry collaboration in technology and research.
India boasts an extensive talent pool and biotechnology infrastructure but must increase R&D investments to unlock its full potential and sustain growth. To maintain a global edge, the nation should support fundamental and applied research funding, nurture innovation, and encourage collaboration among academia, industry, and government, he added.
By focusing on these pivotal areas, India can expedite the growth of its biotechnology industry, harness its talent, and position itself as a leader in global biotechnology innovation and application, Dr. Kumar concluded.